Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Inclusion Criteria:

• Male or female ≥ 18 to ≤ 80 years of age
• National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III)Framingham risk score of 10% or less
• Fasting LDL-C ≥ 100 mg/dL (2.6 mmol/L) and <190 mg/dL
• Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)

Exclusion Criteria:

• History of coronary heart disease
• New York Heart Association (NYHA) III or IV heart failure
• Uncontrolled cardiac arrhythmia
• Uncontrolled hypertension
• Diabetes mellitus (Type 1 diabetes, poorly controlled type 2 diabetes)
• Uncontrolled hypothyroidism or hyperthyroidism